Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma
We aimed to determine the utility of a patient-reported outcome (PRO) as it relates to patient performed testing (PPT) for measuring functional status in multiple myeloma patients after autologous hematopoietic stem cell transplantation (auto-HCT).
Symptom interference on walking (a PRO) was measured by the MD Anderson Symptom Inventory (MDASI). PPT was assessed via 6-min walk test (6MWT). Mixed effects modeling was used to examine (1) the longitudinal relationship between the MDASI score and 6MWT distance and (2) the MDASI scores between patients who did or did not complete the 6WMT. Receiver operating characteristic (ROC) curve analysis was performed to quantify the construct validity of the PRO by differentiating performance status.
Seventy-nine patients were included. Mean 6MWT distance significantly correlated with MDASI-walking interference score (PRO) over the first month of auto-HCT (est = 6.09, p = 0.006). There was a significantly higher completion rate for MDASI versus 6MWT at each time point (p < 0.01). Patients who completed the 6MWT reported less interference on walking during the study period (est = 1.61, p < 0.0001). Finally, the PRO demonstrated significant construct validity for measuring functioning status with MDASI-walking against ECOG-PS as the anchor (AUC = 0.77, 95% CI 0.60–0.94, p = 0.003).
The PRO of MDASI-walking interference is a valid physical functioning measure, correlating with an objective functional measure (6MWT) in MM patients undergoing auto-HCT. As patients with poorer functional status during therapy are less likely to complete PPT, this PRO may offer a more practical quantitative measure of functioning in patients.
KeywordsPatient-reported outcomes (PRO) Patient performed testing (PPT) MD Anderson Symptom Inventory (MDASI) Functional status Auto-HCT
This work was supported in part by the National Cancer Institute of the National Institutes of Health through The University of Texas MD Anderson Cancer Center’s Cancer Center Support Grant, P30 CA016672 (PI: RA DePinho) and program project P01 CA124787 (PI: Charles S. Cleeland).
Compliance with ethical standards
Conflict of interest
The MD Anderson Symptom Inventory (MDASI) is copyrighted and licensed by The University of Texas MD Anderson Cancer Center and by Charles S. Cleeland. The authors declare no other conflicts of interest in this work.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the M.D. Anderson Institutional Review Board.
Informed consent was obtained from all individual participants included in the study.
- 2.Kotronoulas, G., Kearney, N., Maguire, R., Harrow, A., Di Domenico, D., Croy, S., & MacGillivray, S. (2014). What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. Journal of Clinical Oncology, 32(14), 1480–1501.CrossRefPubMedGoogle Scholar
- 4.Penson, R. T., Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., 3rd, Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Method, M., Michael, H., & Tewari, K. S. (2015). Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). The Lancet Oncology, 16(3), 301–311.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Mesa, R. A., Gotlib, J., Gupta, V., Catalano, J. V., Deininger, M. W., Shields, A. L., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Hare, T., Erickson-Viitanen, S., Sun, W., Sandor, V., Levy, R. S., Kantarjian, H. M., & Verstovsek, S. (2013). Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 31(10), 1285–1292.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Tefferi, A., Hudgens, S., Mesa, R., Gale, R. P., Verstovsek, S., Passamonti, F., Cervantes, F., Rivera, C., Tencer, T., & Khan, Z. M. (2014). Use of the Functional Assessment of Cancer Therapy—Anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clinical Therapeutics, 36(4), 560–566.CrossRefPubMedGoogle Scholar
- 7.Wang, X. S., Shi, Q., Shah, N. D., Heijnen, C. J., Cohen, E. N., Reuben, J. M., Orlowski, R. Z., Qazilbash, M. H., Johnson, V. E., Williams, L. A., Mendoza, T. R., & Cleeland, C. S. (2014). Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clinical Cancer Research, 20(5), 1366–1374.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Wang, X. S., Shi, Q., Williams, L. A., Shah, N. D., Mendoza, T. R., Cohen, E. N., Reuben, J. M., Cleeland, C. S., & Orlowski, R. Z. (2015). Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leukemia & Lymphoma, 56(5), 1335–1341.CrossRefGoogle Scholar
- 11.Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P., & Anderson, K. C. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348(26), 2609–2617.CrossRefPubMedGoogle Scholar
- 14.Jones, D., Zhao, F., Fisch, M. J., Wagner, L. I., Patrick-Miller, L. J., Cleeland, C. S., & Mendoza, T. R. (2014). The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clinical Genitourinary Cancer, 12(1), 41–49.CrossRefPubMedGoogle Scholar
- 17.Miyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000). Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine, 161(2 Pt 1), 487–492.CrossRefPubMedGoogle Scholar
- 19.Jones, L. W., Devlin, S. M., Maloy, M. A., Wood, W. A., Tuohy, S., Espiritu, N., Aquino, J., Kendig, T., Michalski, M. G., Gyurkocza, B., Schaffer, W. L., Ali, B., Giralt, S., & Jakubowski, A. A. (2015). Prognostic importance of pretransplant functional capacity after allogeneic hematopoietic cell transplantation. The Oncologist, 20(11), 1290–1297.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Shah, N., Shi, Q., Williams, L. A., Mendoza, T. R., Wang, X. S., Reuben, J. M., Dougherty, P. M., Bashir, Q., Qazilbash, M. H., Champlin, R. E., Cleeland, C. S., & Giralt, S. A. (2016). Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis. Biology of Blood and Marrow Transplantation, 22(2), 226–231.CrossRefPubMedGoogle Scholar
- 21.Castel, L. D., Abernethy, A. P., Li, Y., Depuy, V., Saville, B. R., & Hartmann, K. E. (2007). Hazards for pain severity and pain interference with daily living, with exploration of brief pain inventory cutpoints, among women with metastatic breast cancer. Journal of Pain and Symptom Management, 34(4), 380–392.CrossRefPubMedGoogle Scholar
- 25.Wood, W. A., Le-Rademacher, J., Syrjala, K. L., Jim, H., Jacobsen, P. B., Knight, J. M., Abidi, M. H., Wingard, J. R., Majhail, N. S., Geller, N. L., Rizzo, J. D., Fei, M., Wu, J., Horowitz, M. M., & Lee, S. J. (2016). Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer, 122(1), 91–98.CrossRefPubMedGoogle Scholar
- 27.Jones, L. W., Hornsby, W. E., Goetzinger, A., Forbes, L. M., Sherrard, E. L., Quist, M., Lane, A. T., West, M., Eves, N. D., Gradison, M., Coan, A., Herndon, J. E., & Abernethy, A. P. (2012). Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer, 76(2), 248–252.CrossRefPubMedGoogle Scholar
- 30.Izano, M., Satariano, W. A., Hiatt, R. A., & Braithwaite, D. (2013). The impact of functional limitations on long-term outcomes among African-American and white women with breast cancer: a cohort study. British Medical Journal Open, 3(10), e003232.Google Scholar